Publications dans lesquelles il/elle collabore avec Elixabet Bolaños Mateo (33)

2024

  1. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  2. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

    OncoImmunology, Vol. 13, Núm. 1

2023

  1. Interleukin-18 in cancer immunology and immunotherapy

    Expert Opinion on Therapeutic Targets, Vol. 27, Núm. 11, pp. 1035-1042

  2. Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

    Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198

  3. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682

  4. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 599-616

  5. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  6. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  2. Advances in mRNA-based drug discovery in cancer immunotherapy

    Expert Opinion on Drug Discovery, Vol. 17, Núm. 1, pp. 41-53

  3. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

2021

  1. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  2. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Cellular cytotoxicity is a form of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms

    Cellular and Molecular Immunology, Vol. 17, Núm. 6, pp. 576-586

  3. Exploiting TCR Recognition of Shared Hotspot Oncogene-encoded Neoantigens

    Clinical Cancer Research, Vol. 26, Núm. 6, pp. 1203-1204

2019

  1. Immunotherapeutic effects of intratumoral nanoplexed poly I:C

    Journal for ImmunoTherapy of Cancer, Vol. 7, Núm. 1

  2. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

  3. TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies

    Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631

2018

  1. Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

    OncoImmunology, Vol. 7, Núm. 1